For use with Sofia 2 and Sofia - FDA Emergency Use Authorization.

The Sofia SARS Antigen Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-CoV-2. The Sofia SARS Antigen FIA, with the Sofia 2 and Sofia analyzers, provides automated and objective results in 15 minutes, allowing for testing of patients suspected of COVID-19/2019-nCoV in near-patient testing environments.

• Rapid results to support efficient dispositioning of patients.
• Reliable results without cross-reactivity to seasonal coronaviruses.
• Adjusts to your volume fluctuations. Allows for significant throughput and batching of samples in READ NOW Mode.
• Simple test workflow follows a similar format to CLIA-waived Sofia and Sofia 2 assays.
• Provides automated tracking, data capture, government reporting, and exclusive disease mapping.
• Objective result that eliminates the subjectivity of a visual read.
• Ready for use with Sofia 2 and Sofia for nasal swab procedure.
• Clean, easy to use and dispose of.